Speaker Profile
Ph.D., Dual PhD., CEO and CSO, Phinomics
Biography
Massa Shoura is the CEO and CSO of Phinomics, an innovative company transforming precision medicine by unlocking the potential of circular DNA and integrating genomics with advanced AI. With dual PhDs in Molecular Biology and Biomedical Engineering, Massa has over a decade of expertise in DNA topology, biophysics, and genomics. During her postdoctoral fellowship at Stanford University in Nobel Laureate Dr. Andrew Fires lab, she developed groundbreaking tools for isolating and characterizing circular DNA, earning prestigious fellowships, including the Arnold O. Beckman Fellowship, and securing two granted patents. As a Forbeck Scholar, she advanced cancer genomics by uncovering the role of oncogenic circular DNA amplification. She also spearheaded the sequencing and publication of Pfizer and Moderna COVID-19 vaccine mRNAs, showcasing her commitment to global health. At Phinomics, Massa leads the development of first-in-class precision oncology solutions through the Circulome Atlas, a transformative platform providing unparalleled insights into cancer etiology, progression, and therapeutic resistance.
Session Abstract – PMWC 2026 Silicon Valley
Track Chairs:
Gad Getz, Broad Institute & Alex Morgan, Khosla Ventures
PMWC Award Ceremony
• Greg Brockman, President & Co-Founder, OpenAI
• Steve Wozniak, Co-Founder, Apple
Fireside Chat
• Vinod Khosla, Khosla Ventures
• Greg Brockman, President & Co-Founder, OpenAI
Target Discovery: Beyond Genomics – Revealing Hidden Layers of Biology with AI
• Keynote: Stephen Quake, CZ Biohub
• Chair: Cindy Lawley, Olink
• Aritro Nath, City of Hope
• Massa Shoura, Phinomics
• Omar Serang, DNAnexus
Foundation Models for Human Biology: Accelerating Immunotherapy Discovery Through Multimodal AI
• Ron Alfa, Noetik
Systems Integration for Drug Discovery and AI
• Hugo Lam, Genentech
Interpretable AI Models for Multi-Modal Biomarker Discovery in Drug Development
• Vitalay Fomin, Numenos
Closing the Loop: Coupling AI with In Vivo Validation
• Gabriel Musso, biosymetrics
Interpretable AI for Biomarker Discovery: Accelerating Drug Development
• Chair: Rajat Roy, PATHOMIQ INC
• Shivanni Kummar, MD, OHSU
Can AI Really Create the Next Blockbuster Drug? Closing the Loop from Discovery to Development
• Chair: Amar Das, Guardant Health
• Ari Caroline, Weave Bio
• Dina Katabi, Emerald/MIT
• Andrei Georgescu, Vivodyne
• James Zou, Stanford
Gemini Digital Twins Accelerate Precision Medicine
• Collin Hill, Aitia
Scaling Rare Disease Discovery with AI: From Genomic Data to Therapeutic Insights
• Lisa Gurry, GeneDx
Enabling Targeted Precision Drug & Gene Delivery with Predictive AI
• Andre Watson, Ligandal
Is AI the New Drug?
• Chair: Alex Morgan, Khosla Ventures
• Michael J. Kahana, Nia Therapeutics
